Mumbai: Suven Life Sciences has received patents for three Indian products from the Indian Patent Office (IPO).

The Hyderabad-based pharmaceutical company said that it has received patents for three new chemical entities (NCEs) 208688, 208714 and 209540 for handling troubles that are linked with neuro-degenerative maladies.

The patents granted to the company are valid till 2022.

The patents comprise the group of selective 5-HT compounds discovered by the company, and assistive in taking care of cognitive impairment connected with neuro-degenerative troubles including Alzhemier's, attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia.

In order to find out and develop NCEs for an unmet medical requirement in CNS curative ground, the company is acting as a joint research associate with Elli Lilly, since Sep 2006.

The company’s shares were last trading up Rs 1.95, or 6.23%, at Rs 31.30. The total volume of shares traded at the BSE was 34,085.